
ANTX Stock Forecast & Price Target
ANTX Analyst Ratings
Bulls say
AN2 Therapeutics Inc. has demonstrated a positive trajectory in its clinical development, particularly with its lead compound, epetraborole, which has shown good safety and tolerability in Phase 2 trials, with mild, reversible side effects. The candidate has elicited promising patient-reported outcomes and is anticipated to significantly improve treatment options for both MAC NTM and potentially MAB NTM, indicating a strong market position in addressing these challenging infectious diseases. The positive pre-clinical and clinical results, combined with the potential for epetraborole to fulfill an unmet medical need, bolster the company's outlook in the biopharmaceutical sector.
Bears say
AN2 Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from disappointing results from its lead candidate, epetraborole, and ongoing historical losses without a clear path to profitability. The company encounters various risks, including the likelihood of failing to meet clinical efficacy endpoints and potential litigation that could hamper market exclusivity and commercialization efforts. Additionally, competitive market conditions and internal challenges may hinder AN2's ability to successfully develop and market its pipeline candidates, further exacerbating financial vulnerabilities.
This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ANTX Analyst Forecast & Price Prediction
Start investing in ANTX
Order type
Buy in
Order amount
Est. shares
0 shares